Particle.news
Health ❯ Healthcare ❯ Oncology
HER2-positive Breast Cancer Triple-Negative Breast Cancer Diagnosis Treatment Options HER2-positive Metastatic Breast Cancer Diagnosis and Treatment Clinical Trials Treatment Advances Antibody-Drug Conjugates Camizestrant Prevention Adverse Effects Risk Factors Surgical Treatment Advanced ER-Positive Breast Cancer Screening Programs Survivorship Issues Breast Cancer Screening Clinical Research Public Health Campaigns Therapeutic Advances Patient Management Recurrence Risk Recurrence Prevention Therapeutic Strategies Treatment Monitoring Early Stage Breast Cancer Lipid Metabolism Precision Medicine Warburg Effect Metabolic Reprogramming Glutamine Metabolism Trastuzumab Pamirtecan Triple-Negative Breast Cancer (TNBC) International Congress ESR1-Mutated Breast Cancer Hormone Receptor Positive Breast Cancer Treatment Approvals Micropigmentation Efficacy and Safety PI3K/mTOR Inhibitors Screening Techniques Treatment Regimens Patient Experiences Treatment Strategies Prevention Strategies Awareness Campaigns Datroway Patient Education Genetic Testing Awareness and Prevention Public Health Awareness Patient Care Community Engagement Artificial Intelligence HER2-Positive Breast Cancer Treatment Metastatic Breast Cancer Research Toxicity Management Mastectomy Radical Mastectomy Trastuzumab Entansina Muscle Mass Management Anti-hormonal Therapy HER2-Directed Therapies Targeted Therapy Access to Care Chemotherapy Estrogen Receptor Mutations PIK3CA Mutation Hormonal Therapy Cancer Treatment Centers
Presented at ESMO with a concurrent NEJM publication, the phase 3 data indicate a potential new first-line option for patients ineligible for immunotherapy pending mature survival results.
